Center of Excellence for Blood Cancers and Myeloid Disorders

If you are facing a diagnosis of blood cancer, you want the best care available. The Mount Sinai Health System can help. Our Center of Excellence for Blood Cancer and Myeloid Disorders provides comprehensive and compassionate care for patients with a variety of blood cancers:

  • Acute myeloid leukemia
  • Acute lymphoblastic leukemia
  • Myeloproliferative neoplasms
  • Myelodysplastic syndromes

At Mount Sinai, we believe everyone deserves personalized and excellent care. We develop an individualized treatment plan for you, using the latest advances. We use genetic, epigenetic, cell signaling, and immunologic factors in developing your treatment plan. We are skilled in stem cell transplantation. And we are expert at overcoming graft-versus-host-disease, one of the main challenges of stem cell transplant.

Meet Our Team

Led by John O. Mascarenhas, MD, our staff of more than 40 experts has everyone you need for successful diagnosis and treatment. We have physicians, laboratory investigators, clinical investigators, physician assistants, nurse practitioners, nurses, and social workers. Working as a team, we harness the latest scientific advances to give you the best possible outcome. When needed, we tap into the expertise of other scientists and clinical specialists in the Health System. Our team includes:

Leukemia Specialists

Stem Cell Transplantation Experts

Transplantation Physician Scientists

Laboratory Scientists

Why Mount Sinai

Mount Sinai is at the forefront of blood cancer research. We are skilled in identifying risk factors for blood cancers and developing treatments using targeted therapies and immunotherapies. And we use our own laboratory and clinical discoveries to help you and your loved ones. With our research, we help patients at Mount Sinai and around the world. We continue to explore new methods of diagnosis and treatment. We are pioneering new forms of cellular therapy such as vaccines, bispecific antibodies, CAR T-cell therapies (led by Keren Osman, MD), and natural killer cell-based therapies.

Our physician group has received national recognition through a National Cancer Institute-sponsored Myeloproliferative Neoplasm Research Consortium grant. This grant funds scientists and physicians from multiple institutions who focus on translating laboratory findings into groundbreaking treatments.

Our research efforts are not new. Mount Sinai has a rich history of making significant contributions to the science and clinical care of patients with blood cancers. Esteemed luminaries, past and present, include:

In addition, we are training future clinical and research leaders to improve the care of patients with blood cancers, now and into the future.